A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Sponsor:
- Kartos Therapeutics
- Sponsor Study ID:
- KRT-232-115
- CTO #:
- 104063
- NCT Number:
- NCT06479135
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Other Hematopoietic
- Study Objectives:
- To compare SVR35 between Arm 1 and Arm 2. To compare TSS50 between Arm 1 and Arm 2. To compare SVR25 between Arm 1 and Arm 2. To compare TSS30 between Arm 1 and Arm 2.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Coltoff, Alexander, at coltoff@musc.edu
- Study Coordinator, Ward, Sarah, at saw306@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina